Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Gross Margin (2016 - 2019)

Historic Gross Margin for Cardiff Oncology (CRDF) over the last 7 years, with Q4 2019 value amounting to 100.0%.

  • Cardiff Oncology's Gross Margin changed 0.0% to 100.0% in Q4 2019 from the same period last year, while for Dec 2019 it was 100.0%, marking a year-over-year increase of 1579200.0%. This contributed to the annual value of 100.0% for FY2019, which is 1579200.0% up from last year.
  • Cardiff Oncology's Gross Margin amounted to 100.0% in Q4 2019, which was down 0.0% from 100.0% recorded in Q3 2019.
  • In the past 5 years, Cardiff Oncology's Gross Margin registered a high of 100.0% during Q4 2018, and its lowest value of 3809.9% during Q2 2015.
  • Its 5-year average for Gross Margin is 1130.97%, with a median of 274.77% in 2017.
  • Per our database at Business Quant, Cardiff Oncology's Gross Margin tumbled by -28566600bps in 2015 and then soared by 33157300bps in 2017.
  • Cardiff Oncology's Gross Margin (Quarter) stood at 2349.13% in 2015, then plummeted by -46bps to 3423.08% in 2016, then soared by 97bps to 107.35% in 2017, then surged by 193bps to 100.0% in 2018, then changed by 0bps to 100.0% in 2019.
  • Its last three reported values are 100.0% in Q4 2019, 100.0% for Q3 2019, and 100.0% during Q2 2019.